INDEGENE
Back to Balance Sheet
|
INDEGENE Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹56 Cr | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr |
What is the latest Total Non-Current Liabilities ratio of INDEGENE ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹56 Cr |
| Mar2024 | ₹435 Cr |
| Mar2023 | ₹584 Cr |
| Mar2022 | ₹80 Cr |
| Mar2021 | ₹27 Cr |
How is Total Non-Current Liabilities of INDEGENE Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹56 Cr | -87.12 | |
| Mar2024 | ₹435 Cr | -25.54 | |
| Mar2023 | ₹584 Cr | 630.10 | |
| Mar2022 | ₹80 Cr | 198.58 | |
| Mar2021 | ₹27 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDEGENE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDEGENE | ₹12,555.7 Cr | -2.8% | -0.2% | -11.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹412,086.0 Cr | -1.5% | -4.8% | -4.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,616.0 Cr | -1.9% | -1.6% | 11.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,361.0 Cr | 0.3% | 1.6% | 12.1% | Stock Analytics | |
| CIPLA | ₹120,713.0 Cr | -1.2% | -2% | 2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,881.0 Cr | -1.2% | 1.5% | -6.1% | Stock Analytics | |
INDEGENE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | -2.8% |
-0.2% |
-11.8% |
| SENSEX | -0.3% |
-1.1% |
7.8% |
You may also like the below Video Courses